Loading…
Ernexa Therapeutics Inc. is projected to decline to $9.73 by 2027, a -13% move from its current price of $11.14. ERNA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $10.14 | $11.15 | $12.25 | +0.06% |
| May 30 | $9.76 | $11.15 | $12.75 | +0.12% |
| May 31 | $9.47 | $11.16 | $13.15 | +0.19% |
| Jun 1 | $9.24 | $11.17 | $13.50 | +0.25% |
| Jun 2 | $9.04 | $11.17 | $13.81 | +0.31% |
| Jun 3 | $8.87 | $11.18 | $14.10 | +0.37% |
| Jun 4 | $8.71 | $11.19 | $14.37 | +0.44% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.71 | $11.19 | $14.37 | +0.44% |
| Week 2 | $7.89 | $11.24 | $16.01 | +0.88% |
| Week 3 | $7.31 | $11.29 | $17.42 | +1.32% |
| Week 4 | $6.87 | $11.34 | $18.71 | +1.76% |
| Week 5 | $6.50 | $11.39 | $19.93 | +2.20% |
| Week 6 | $6.19 | $11.44 | $21.12 | +2.65% |
| Week 7 | $5.92 | $11.49 | $22.28 | +3.10% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ernexa Therapeutics Inc. is a preclinical-stage healthcare company focused on iMSC therapies for cancer and autoimmune diseases. The lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.
The company has a license agreement with Factor Bioscience Limited. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025.
Ernexa Therapeutics Inc. (ERNA) is currently priced at $11.14 with a market capitalization of $12.99M and is ranked 5025 by market position. The near-term outlook is mixed, with neutral sentiment projected for the early years and a path toward higher levels later in the forecast horizon.
In the forecast, the 2026 average price is $11.14, with a 2029 average of $8.55 and a 2030 average of $12.15. The long-range view shows stronger upside, with 2040 average $14.80 and 2050 average $26.85, suggesting potential multi-year appreciation amid shifting sentiment toward bullish in the farther horizon.
Price guidance over the years includes a max forecast of $13.59 for 2026, rising to $21.19 by 2030, $32.55 by 2040, and $61.76 by 2050, with corresponding ROI figures of 0% in 2026, 9.1% in 2030, 32.9% in 2040, and 141.1% in 2050. The asset remains within a wide long-term range and exhibits volatility characteristics across the forecast window.
A major floor 66.4% below — a decisive break under it would weaken the trend.
The nearest floor, 66.4% below — buyers have tended to step in here.
The nearest ceiling, 22.4% above — a clean break opens room to run.
A major ceiling 178.3% above — clearing it would confirm fresh momentum.
Key ERNA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ERNA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.68 | Sell | $11.51 | Sell |
| MA 10 | $11.75 | Sell | $11.05 | Buy |
| MA 20 | $8.90 | Buy | $9.67 | Buy |
| MA 50 | $6.75 | Buy | $9.02 | Buy |
| MA 100 | $12.47 | Sell | $13.59 | Sell |
| MA 200 | $23.24 | Sell | $38.91 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.98 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 47.31 | Neutral |
| Williams %R (14) | -38.79 | Info |
| MACD (12,26,9) | 0.18 | Buy |
| ROC (12) | 47.94 | Buy |
| Bollinger %B (20,2) | 0.66 | Neutral |
| Stochastic %K (14) | 61.21 | Neutral |
| TRIX (15) | 3.40 | Buy |
| Awesome (5,34) | 4.43 | Buy |
| Ultimate (7,14,28) | 40.38 | Neutral |
| Momentum (10) | -0.87 | Sell |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 11.59 | Sell |
| ADX (14) | 33.10 | Buy |
| ATR (14) | 0.89 | Info |
The near-term technical picture is bullish in sentiment but exhibits a broad trading range. The RSI14 sits at 60, providing a footing for momentum without extreme overbought conditions.
The chart shows a 50-day simple moving average of $6.75 and a 200-day simple moving average of $23.24, framing current price action against a broad trend. The 30-day range spans from a low of $5.97 to a high of $20.79, indicating substantial daily variability within the month.
Support is identified at $3.74 and resistance at $13.63, with volatility that can widen price swings. Annualized volatility stands at 200%, underscoring the heightened risk and potential for rapid moves in either direction.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.74 | $11.14 | $13.59 | 0% | Neutral | |
| $7.00 | $9.73 | $14.62 | -13% | Neutral | |
| $6.40 | $9.44 | $15.09 | -15% | Bearish | |
| $5.51 | $8.55 | $14.32 | -23% | Bearish | |
| $7.47 | $12.15 | $21.19 | +9% | Neutral | |
| $7.70 | $13.09 | $23.61 | +18% | Neutral | |
| $7.10 | $12.58 | $23.39 | +13% | Neutral | |
| $6.80 | $12.55 | $23.97 | +13% | Neutral | |
| $5.35 | $10.26 | $20.09 | -8% | Neutral | |
| $5.52 | $11.01 | $22.06 | -1% | Neutral | |
| $6.66 | $14.80 | $32.55 | +33% | Bullish | |
| $12.08 | $26.85 | $61.76 | +141% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.74 | $11.14 | $13.16 | +0.00% |
| June 2026 | $9.40 | $11.28 | $14.01 | +1.23% |
| July 2026 | $9.67 | $11.79 | $15.03 | +4.56% |
| August 2026 | $9.15 | $11.31 | $14.69 | -4.11% |
| September 2026 | $8.63 | $10.79 | $14.23 | -4.60% |
| October 2026 | $8.75 | $11.05 | $14.78 | +2.42% |
| November 2026 | $8.52 | $10.86 | $14.71 | -1.69% |
| December 2026 | $7.72 | $9.92 | $13.59 | -8.68% |
Click any year to see its month-by-month ERNA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ERNA is projected to trade between $3.74 and $13.59, averaging $11.14 — a potential gain of 0% from today's $11.14. A consolidation phase looks the most probable path here.
Ernexa Therapeutics Inc.'s 2027 outlook centres on $9.73, within a $7.00 to $14.62 range. That is -13% versus the projected 2026 average. That marks a -13% change versus current levels. Price action looks broadly range-bound.
By 2028, ERNA could reach as high as $15.09, with a base case around $9.44 and support toward $6.40 — roughly -15% from $11.14. Expect choppier, lower action through this leg of the cycle.
Expect ERNA to range from $5.51 to $14.32 through 2029. The $8.55 average target implies a -23% move from current prices. That is -9% versus the projected 2028 average. A cyclical pullback looks likely — prices rarely move in a straight line.
The ERNA price prediction for 2030 points to an average of $12.15 (low $7.47, high $21.19) — a potential gain of +9% on today's $11.14. A consolidation phase looks the most probable path here.
In 2031, ERNA is projected to trade between $7.70 and $23.61, averaging $13.09 — a potential gain of +18% from today's $11.14. That is up +8% on the projected 2030 average. Price action looks broadly range-bound.
Ernexa Therapeutics Inc.'s 2032 outlook centres on $12.58, within a $7.10 to $23.39 range. That is -4% versus the projected 2031 average. That marks a +13% change versus current levels. A consolidation phase looks the most probable path here.
By 2033, ERNA could reach as high as $23.97, with a base case around $12.55 and support toward $6.80 — roughly +13% from $11.14. Price action looks broadly range-bound.
Expect ERNA to range from $5.35 to $20.09 through 2034. The $10.26 average target implies a -8% move from current prices. That is -18% versus the projected 2033 average. A consolidation phase looks the most probable path here.
The ERNA price prediction for 2035 points to an average of $11.01 (low $5.52, high $22.06) — a potential decline of -1% on today's $11.14. Price action looks broadly range-bound.
In 2040, ERNA is projected to trade between $6.66 and $32.55, averaging $14.80 — a potential gain of +33% from today's $11.14. That is up +34% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Ernexa Therapeutics Inc.'s 2050 outlook centres on $26.85, within a $12.08 to $61.76 range. That is up +81% on the projected 2040 average. That marks a +141% change versus current levels. Momentum favours further upside here.
Investing $1,000 in ERNA today (≈ 89.766607 ERNA) could be worth
$2,410.49
+$1,410.49 (+141%) by 2050 · US Dollar
Based on the average projected ERNA price of $26.85 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ERNAwould be worth at today's price.
$1,000 invested in ERNA on May 27, 2025 (≈ 11.111111 ERNA) would be worth
$123.78
-$876.22 (-87.6%) today · 0.12× · US Dollar
Based on a ERNA entry price of $90 vs. today's $11.14.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $11.4 | $977.19 | -2.3% |
| 1 month ago | $5 | $2,228 | +122.8% |
| 3 months ago | $7.5 | $1,485.33 | +48.5% |
| 6 months ago | $33.75 | $330.07 | -67.0% |
| 1 year ago | $90 | $123.78 | -87.6% |
| All time (5.0y) ago | $124,725 | $0.09 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ERNA forecast.
Our base-case forecast reaches $22.00 around 2050.
Implied market cap at $22.00: $25.66M
The multi-year forecast depicts a progression from neutral to more positive momentum in the outer years. The 2030 forecast shows an average price of $12.15 with a min of $7.47 and a max of $21.19, and a return outlook of 9.1% alongside a neutral sentiment.
Beyond 2030, the outlook improves, with 2040 projecting an average of $14.80 and a max of $32.55, yielding a 32.9% ROI and a bullish sentiment. By 2050, the average is forecast at $26.85 with a max of $61.76 and a 141.1% ROI, also with bullish sentiment.
These figures imply a gradual appreciation in the longer term, tempered by near-term volatility and neutral to cautiously constructive sentiment in the 2026–2035 period. As with all forecasts, these are estimates rather than guarantees and should be considered in light of broader market conditions and company-specific developments.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $12.15, with a min of $7.47 and a max of $21.19, and an ROI of 9.1% with neutral sentiment.
Forecasts indicate a neutral stance through 2026 and 2030 with gradual upside thereafter (2040: avg $14.80, ROI 32.9%; 2050: avg $26.85, ROI 141.1%), but these are estimates, not guarantees, and depend on future conditions.
Yes, the max forecast reaches $21.19 in 2030, $32.55 in 2040, and $61.76 in 2050, indicating potential for higher price levels under the forecast assumptions.
Current price is $11.14 and market cap is $12.99M, with a rank of 5025.
The 14-day RSI is 60 and sentiment is BULLISH. The 50-day SMA is $6.75 and the 200-day SMA is $23.24. The 30-day range is $5.97 to $20.79, with support at $3.74 and resistance at $13.63; annualized volatility is 200%.
Ernexa Therapeutics Inc. Community Discussion
0Share your Ernexa Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.